Do lower cost oral weight loss GLP-1 drugs change coverage decisions?
By Dr. Martin Fornataro, Pharm D., and David Broome, Health Consultant
For most self-funded health plans, weight loss drugs have typically been excluded from coverage. These medications were expensive, the eligible population was large, and the long-term value of covering them across a broad member base was unclear. But with the recent FDA approval of two lower cost GLP-1 weight loss tablets —oral Wegovy and Foundayo, the coverage calculation is being tested. Both options cost far less than injectable alternatives. Self-pay prices for oral Wegovy and Foundayo range from $149 to $349 per month, compared with the $1,349 per month list price for injectable Wegovy and about $1,100 per month for injectable Mounjaro.
For trustees and plan sponsors, the issue is no longer only whether these drugs are effective. The question is whether their lower cost now makes coverage a sound investment in the plan’s health and its members’ health.
The drugs work — that part is clear
The clinical evidence for the GLP1 weight loss drugs is strong. In clinical trials, participants taking oral Wegovy lost an average of 13.6% of their body weight over about 15 months.¹ Participants taking Foundayo lost an average of 11.2% over about 17 months.²
Beyond weight loss, a separate cardiovascular trial showed that injectable semaglutide reduced heart attacks, strokes, and cardiovascular deaths by 20% in patients who were overweight or obese and already had heart disease—the first time a GLP1 weight loss drug demonstrated that kind of heart protection in people without diabetes.³
The math is better, but not simple
At injectable prices, the financial case was difficult to make. One claims analysis found that GLP-1 users saw about $560 per year in lower medical costs, but their prescriptions added $6,540 per year in new drug spending.⁴ Oral weight loss tablets narrow that gap. But narrowing the gap and closing it are two different things—and the difference comes down to two questions: Do members actually stay on the medication long enough to achieve long term benefit? Is it cost-effective to cover the new lower cost GLP1 weight loss drugs?
The persistence and long-term coverage challenges
This is where the conversation gets complicated. GLP1 weight loss drugs work in the stomach to slow down how quickly the stomach empties, and in the brain to reduce hunger and cravings. This combination causes the patient to eat less and therefore lose weight. Patients must supplement GLP1 drug use with meaningful behavioral and lifestyle changes. Once the GLP1 weight loss drugs are stopped, weight gain is inevitable. Published data show that patients who discontinue their GLP1 drug regain approximately two-thirds of the weight they lost within 12 months.⁷
And in the real world, most people do stop. The largest published study of commercially insured adults found that only about one in four were still taking a GLP-1 after one year. After three years, only about 1 in 12 continued.⁶ As a result, plans may be paying for months of medication for members who ultimately stop and regain the weight they lost.
Some clinicians see GLP1 weight loss medications as indefinite treatments—like blood pressure or cholesterol medications.
Risks worth noting
GLP1 weight loss drugs are not without side effects. Nausea is common early on, though it typically fades. More serious documented risks include gallstones and gallbladder inflammation, stomach paralysis, and loss of muscle mass alongside fat. Both oral Wegovy and Foundayo carry the FDA’s most serious warning category—a boxed warning—for thyroid C-cell tumors based on animal studies. Most clinical trials of these drugs have been funded by the manufacturers, and long-term safety data beyond two to four years remain limited.⁸
Where this leaves plan sponsors
Lower-cost oral weight loss GLP1 drugs help, but the key issues are scale and persistence: 34% of non-elderly adults with employer-sponsored insurance have a BMI that could qualify them,⁵ and many stop treatment. Coverage decisions should focus on total spend—how many start, how many stay, and whether reliable medical savings projections offset drug costs.
Prior authorization, a required step to determine for GLP1 coverage, and periodic clinical review may help target the right patients for GLP1 weight loss coverage; whether real-world use delivers sustainable ROI remains uncertain.
This article is intended for informational purposes only and does not constitute legal, medical, or benefits advice. All data cited is drawn from published studies, FDA filings, and publicly available research as of May 2026.
Footnotes
¹ Wharton S, et al. OASIS 4. NEJM, Sept 2025 (N=307; wk 64).
² Wharton S, et al. ATTAIN‑1. NEJM, Sept 2025 (N=3,127; 72 wks).
³ Lincoff AM, et al. SELECT. NEJM, 2023 (N=17,604; 39.8 mos).
⁴ AssuredPartners. GLP‑1 cost‑effectiveness case study, Feb 2025.
⁵ Peterson‑KFF Health System Tracker, Oct 2025 (34% BMI‑eligible).
⁶a Xie L, et al. JAMA Netw Open, Mar 2026 (N=126,984; 12‑mo persistence 24.5%).
⁶b Prime Therapeutics, Jun 2025 (3‑yr persistence 8%; N=5,780).
⁷ Wilding JPH, et al. STEP 1 extension. Diabetes Obes Metab, 2022; Aronne LJ, et al. SURMOUNT‑4. JAMA, 2024.
⁸ Cochrane (WHO‑commissioned GLP‑1 reviews), Oct 2025; WHO GLP‑1 obesity guideline, Dec 2025.